Cargando…
The effect of azoximer bromide (Polyoxidonium(®)) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study
A clinical need for aetiotropic coronavirus disease (COVID-19) treatments is required. The immune modulator azoximer bromide (AZB; Polyoxidonium(®)) is indicated in Russia for use against acute viral infections and during remission. In this study, adults hospitalized with COVID-19 (n=32) received AZ...
Autores principales: | Efimov, Sergey V, Matsiyeuskaya, Natallia V, Boytsova, Olga V, Akhieva, Lyudmila Yu, Kvasova, Elena I, Harrison, Francisco, Karpova, Yulia S, Tikhonov, Anton, Khomyakova, Nadezhda F, Hardman, Tim, Rossi, Jean-François |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007208/ https://www.ncbi.nlm.nih.gov/pubmed/33828607 http://dx.doi.org/10.7573/dic.2020-11-1 |
Ejemplares similares
-
Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19
por: Efimov, Sergey V, et al.
Publicado: (2022) -
Corrigendum: The effect of azoximer bromide (Polyoxidonium(®)) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study
Publicado: (2021) -
Azoximer Bromide: Mystery, Serendipity, and Promise
por: Grivtsova, Lyudmila Yuryevna, et al.
Publicado: (2021) -
Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine.
por: Kompier, Ronald, et al.
Publicado: (2022) -
Improving the Efficacy of Antimicrobials against Biofilm-Embedded Bacteria Using Bovine Hyaluronidase Azoximer (Longidaza(®))
por: Trizna, Elena, et al.
Publicado: (2021)